Profile data is unavailable for this security.
About the company
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.
- Revenue in USD (TTM)0.00
- Net income in USD-39.77m
- Incorporated2010
- Employees22.00
- LocationCitius Pharmaceuticals Inc11 Commerce Dr Fl 1CRANFORD 07016-3501United StatesUSA
- Phone+1 (908) 967-6677
- Websitehttps://www.citiuspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oramed Pharmaceuticals, Inc. | 0.00 | 20.86m | 94.18m | 15.00 | 4.62 | 0.530 | 4.49 | -- | 0.4999 | 0.4999 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | 12.19 | -- | 12.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
Immuneering Corp | 0.00 | -56.07m | 95.19m | 66.00 | -- | 1.44 | -- | -- | -1.91 | -1.91 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -55.52 | -- | -59.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
Skye Bioscience Inc | 0.00 | -42.29m | 95.26m | 11.00 | -- | 1.21 | -- | -- | -3.91 | -3.91 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -94.50 | -232.67 | -129.40 | -- | -- | -- | -- | -- | -- | -323.10 | 0.0626 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
Werewolf Therapeutics Inc | 9.28m | -53.73m | 95.71m | 45.00 | -- | 0.9201 | -- | 10.31 | -1.35 | -1.35 | 0.236 | 2.38 | 0.0548 | -- | 2.48 | 197,510.60 | -31.70 | -- | -34.39 | -- | -- | -- | -578.80 | -- | -- | -- | 0.1948 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
Clearside Biomedical Inc | 7.52m | -33.46m | 97.92m | 30.00 | -- | -- | -- | 13.01 | -0.497 | -0.497 | 0.1119 | -0.3785 | 0.2058 | -- | 59.01 | 250,800.00 | -91.51 | -63.57 | -107.97 | -81.77 | 95.06 | -- | -444.66 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
Boundless Bio Inc | 0.00 | -57.72m | 97.92m | 72.00 | -- | 0.5463 | -- | -- | -2.60 | -2.60 | 0.00 | 8.05 | 0.00 | -- | -- | 0.00 | -33.64 | -- | -35.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
Sagimet Biosciences Inc | 2.00m | -29.25m | 101.09m | 10.00 | -- | 0.5467 | -- | 50.55 | -1.18 | -1.18 | 0.078 | 5.74 | 0.019 | -- | -- | 200,000.00 | -27.79 | -- | -29.32 | -- | -- | -- | -1,462.55 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
Citius Pharmaceuticals Inc | 0.00 | -39.77m | 103.00m | 22.00 | -- | 1.20 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
Eledon Pharmaceuticals Inc | 0.00 | -88.51m | 105.09m | 20.00 | -- | -- | -- | -- | -2.52 | -2.52 | 0.00 | -0.2208 | 0.00 | -- | -- | 0.00 | -77.89 | -38.44 | -81.83 | -39.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 54.16 | -- | -- | -- |
Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 105.15m | 9.00 | -- | 18.99 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
Relmada Therapeutics Inc | 0.00 | -86.76m | 105.91m | 20.00 | -- | 1.72 | -- | -- | -2.88 | -2.88 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -89.88 | -- | -100.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
Leap Therapeutics Inc | 0.00 | -60.34m | 105.99m | 54.00 | -- | 1.61 | -- | -- | -2.00 | -2.00 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -67.81 | -80.06 | -80.19 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
Checkpoint Therapeutics Inc | 78.00k | -42.47m | 108.49m | 23.00 | -- | -- | -- | 1,390.94 | -1.50 | -1.50 | 0.0027 | -0.372 | 0.0111 | -- | 2.17 | 3,391.30 | -606.33 | -142.43 | -- | -342.79 | -- | -- | -54,444.87 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
ALX Oncology Holdings Inc | 0.00 | -171.44m | 109.03m | 74.00 | -- | 0.6815 | -- | -- | -3.64 | -3.64 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -74.45 | -34.34 | -84.76 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0734 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
Annovis Bio Inc | 0.00 | -43.02m | 110.57m | 6.00 | -- | -- | -- | -- | -4.42 | -4.42 | 0.00 | -0.1494 | 0.00 | -- | -- | 0.00 | -308.78 | -106.31 | -395.89 | -124.71 | -- | -- | -- | -- | -- | -51.53 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 8.12m | 4.49% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 6.89m | 3.81% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.21m | 1.22% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.65m | 0.91% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 1.12m | 0.62% |
American Portfolios Advisors, Inc.as of 31 Mar 2024 | 895.55k | 0.50% |
Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 356.99k | 0.20% |
BlackRock Investment Management LLCas of 31 Mar 2024 | 334.13k | 0.19% |
BlackRock Advisors LLCas of 31 Mar 2024 | 227.43k | 0.13% |
Hightower Advisors LLCas of 31 Mar 2024 | 209.86k | 0.12% |